Key IPO Details
| Category | Details |
| IPO Date | March 24 – March 27, 2026 |
| Price Band | ₹372 – ₹392 per share |
| Lot Size | 38 Shares (Minimum ₹14,896) |
| Face Value | ₹5 per share |
| Issue Size | ~₹400+ Crore (₹285 Cr Fresh Issue + 3.16M shares OFS) |
| Listing At | BSE, NSE |
| Registrar | Bigshare Services Pvt Ltd |
Important Dates (Tentative)
- Anchor Bidding: March 23, 2026
- Allotment Finalization: March 30, 2026
- Refund Initiation: April 1, 2026
- Listing Date: April 2, 2026
Grey Market Premium (GMP)
As of March 17, 2026, the GMP for Sai Parenterals is currently reported at ₹0 (Flat). This indicates that while there is steady interest in the pharma sector, the grey market is currently awaiting more subscription data before assigning a premium.
Business & Financials
- Operations: Incorporated in 2001, the company is a Hyderabad-based pharmaceutical formulations player focusing on branded generics and CDMO (Contract Development and Manufacturing Organization) services.
- Therapeutic Areas: Their portfolio includes cardiovascular, neuropsychiatry, anti-diabetic, and antibiotics, with a specialty in complex dosage forms like sterile injectables.
- Financial Growth: Revenue grew to ₹163.74 Crore in FY25 with a Profit After Tax (PAT) of ₹14.24 Crore. The company has shown a significant improvement in its PAT margin, which rose to approximately 8.84%.
- Acquisition: The company recently acquired a controlling stake in Noumed Pharmaceuticals (Australia) to strengthen its global footprint in regulated markets.
Investor Quotas
- QIB: 50% of the net offer
- Retail: 35% of the net offer
- Non-Institutional (NII): 15% of the net offer
Smart Takeaway: The IPO is priced at a premium compared to its NAV (Net Asset Value) of ~₹36. Investors should monitor the subscription levels from institutional buyers (QIBs) on Day 1 and Day 2 to gauge market confidence in its high-growth pharma CDMO model.
